Hanon S.a· Vanderhelst E.a· Buls N.b· Verbanck S.a

Author affiliations

aRespiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium
bDepartment of Radiology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: December 27, 2021
Accepted: June 16, 2022
Published online: August 26, 2022

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 2

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES

Abstract

Background: Dry powder inhaler (DPI) use requires sufficient peak inspiratory flow over the DPI internal resistance (PIFR). Objectives: We examined whether spirometric peak inspiratory flow (PIFspiro) could serve to predict PIFR in patients with obstructive lung disease. Method: Thirty healthy nonsmokers and 140 stable outpatients (70 COPD, 70 asthma) performed spirometry according to the 2019 ERS/ATS spirometry update, yielding PIFspiro. Using a PIFR measurement device with varying orifices, all subjects’ PIFR values were recorded for 5 predefined resistance levels, characterized by 5 orifice cross sections (SR). A test group including all healthy subjects, 30 of the asthma, and 30 of the COPD patients was used to establish the relationship between PIFR and both PIFspiro and SR by multiple regression. A validation group including the remaining 40 asthma and 40 COPD patients, served to verify whether their predicted PIFR value corresponded to the measured PIFR for each resistance level. Results: The asthma (FEV1 = 78 ± 17 [SD] %pred) and COPD (FEV1 = 46 ± 17 [SD] %pred) patients under study had varying airway obstruction. In the test group, PIFR could be predicted by ln[PIFspiro] (p < 0.0001), SR (p < 0.0001), and SR2 (p = 0.006), with an adjusted R2 = 0.71. In the validation group, estimated PIFR did not significantly differ from measured PIFR (p > 0.05 for the 5 resistance levels). Conclusions: We propose a simple method to predict PIFR for a range of common DPI resistances, based on the device characteristics and on the patient’s characteristics reflected in PIFspiro. As such, routine spirometry can serve to estimate a patient’s specific PIFR without the need for additional testing.

© 2022 S. Karger AG, Basel

References Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PR, Levy ML, Pedersen S, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011 Jul;105(7):1099–103. Janson C, Henderson R, Löfdahl M, Hedberg M, Sharma R, Wilkinson AJK, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020 Jan;75(1):82–4. Baloira A, Abad A, Fuster A, García Rivero JL, García-Sidro P, Márquez-Martín E, et al. Lung deposition and inspiratory flow rate in patients with chronic obstructive pulmonary disease using different inhalation devices: a systematic literature review and expert opinion. Int J Chron Obstruct Pulmon Dis. 2021 Apr;16:1021–33. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019 Mar;15:461–72. Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016 Sep;118:65–75. Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017 Dec;30(6):381–7. Haughney J, Lee AJ, McKnight E, Pertsovskaya I, O’Driscoll M, Usmani OS, et al. Peak inspiratory flow measured at different inhaler resistances in patients with asthma. J Allergy Clin Immunol Pract. 2021 Feb;9(2):890–6. Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020 Jan;161:105857. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011 Jun;105(6):930–8. Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017 Jul–Aug;5(4):1071–81.e9. Sulaiman I, Greene G, MacHale E, Seheult J, Mokoka M, D'Arcy S, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018 Jan 4;51(1):1701126. Sulaiman I, Cushen B, Greene G, Seheult J, Seow D, Rawat F, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017 May;195(10):1333–43. Mahler DA, Halpin DMG. Peak inspiratory flow as a predictive therapeutic biomarker in COPD. Chest. 2021 Aug;160(2):491–8. Wu AC, Kiley JP, Noel PJ, Amur S, Burchard EG, Clancy JP, et al. Current status and future opportunities in lung precision medicine research with a focus on biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research statement: executive summary. Am J Respir Crit Care Med. 2018 Dec;198(12):e116–36. Chrystyn H, Audibert R, Keller M, Quaglia B, Vecellio L, Roche N, et al. Real-life inhaler adherence and technique: time to get smarter. Respir Med. 2019 Oct–Nov;158:24–32. Sanders MJ. Guiding inspiratory flow: development of the in-check DIAL G16, a tool for improving inhaler technique. Pulm Med. 2017;2017:1–7. Jõgi R, Mattila L, Vahteristo M, Takala A, Lähelmä S, Vartiainen VA, et al. Inspiratory flow parameters through dry powder inhalers in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD): device resistance does not limit use in COPD. Int J Chron Obstruct Pulmon Dis. 2021 Apr;16:1193–201. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philps T, Troosters T, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008 Jan;31(1):78–83. Farkas Á, Szipőcs A, Horváth A, Horváth I, Gálffy G, Varga J, et al. Establishment of relationships between native and inhalation device specific spirometric parameters as a step towards patient tailored inhalation device selection. Respir Med. 2019 Jul–Aug;154:133–40. Duarte AG, Tung L, Zhang W, Hsu ES, Kuo YF, Sharma G, et al. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstr Pulm Dis. 2019 Jul;6(3):246–55. Hanon S, Vanderhelst E, Vincken W, Schuermans D, Verbanck S. Peak in- and expiratory flow revisited: reliability and reference values in adults. Respiration. 2021;100(1):11–8. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343–73. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American thoracic society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019 Oct;200(8):e70–88. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324–43. Broeders ME, Molema J, Hop WC, Vermue NA, Folgering HT. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004 Dec;98(12):1173–9. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):174–9. Schuermans D, Hanon S, Wauters I, Verbanck S, Vandevoorde J, Vanderhelst E, et al. Impact of a single 10 min education session on asthma control as measured by ACT. Respir Med. 2018 Oct;143:14–7. Tiddens HA, Geller DE, Challoner P, Speirs RJ, Kesser KC, Overbeek SE, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. Winter 2006;19(4):456–65. Sarinas PS, Robinson TE, Clark AR, Canfield J Jr, Chitkara RK, Fick RB Jr, et al. Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest. 1998 Oct;114(4):988–92. Barnes CN, Mahler DA, Ohar JA, Lombardi DA, Crater GD. Peak inspiratory flows: defining repeatability limits and a predictive equation for different inhalers. Chest. 2020 Oct;158(4):1413–9. Article / Publication Details

First-Page Preview

Received: December 27, 2021
Accepted: June 16, 2022
Published online: August 26, 2022

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 2

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.